Surgical-site infections (SSIs) following caesarean sections (CS) represent a significant health complication with a global prevalence between 5 and 10 percent. This issue is particularly prevalent in low- and middle-income countries (LMICs) due to limited access to medical surveillance and routine microbiology, often resulting in largely empirical antibiotic treatments. LMICs are disproportionately impacted, necessitating further…